On June 17, 2024, the Food and Drug Administration approved 21-valent pneumococcal conjugate vaccine (PCV) (PCV21; CAPVAXIVE; Merck Sharp & Dohme, LLC) for adults aged ≥18 years. PCV21 does not contain certain serotypes that are included in other licensed pneumococcal vaccines but adds eight new serotypes. The Advisory Committee on Immunization Practices (ACIP) recommends use of a PCV for all adults aged ≥65 years, as well as adults aged 19-64 years with certain risk conditions for pneumococcal disease if they have not received a PCV or whose vaccination history is unknown. Previously, options included either 20-valent PCV (PCV20; Prevnar20; Wyeth Pharmaceuticals, Inc.) alone or a 15-valent PCV (PCV15; VAXNEUVANCE; Merck Sharp & Dohme, LLC) in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax23; Merck Sharp & Dohme, LLC). Additional recommendations for use of PCV20 exist for adults who started their pneumococcal vaccination series with 13-valent PCV (PCV13; Prevnar13; Wyeth Pharmaceuticals, Inc.). The ACIP Pneumococcal Vaccines Work Group employed the Evidence to Recommendations framework to guide its deliberations on PCV21 vaccination among U.S. adults. On June 27, 2024, ACIP recommended a single dose of PCV21 as an option for adults aged ≥19 years for whom PCV is currently recommended. Indications for PCV have not changed from previous recommendations. This report summarizes evidence considered for these recommendations and provides clinical guidance for use of PCV21.

中文翻译：

---

美国成人使用 21 价肺炎球菌结合疫苗：免疫实践咨询委员会的建议 - 美国，2024 年。


2024 年 6 月 17 日，美国食品药品监督管理局批准了 21 价肺炎球菌结合疫苗 （PCV） （PCV21;CAPVAXIVE;Merck Sharp & Dohme， LLC）适用于≥18岁的成年人。PCV21 不包含其他获得许可的肺炎球菌疫苗中包含的某些血清型，但增加了 8 种新血清型。免疫接种实践咨询委员会 （ACIP） 建议所有 ≥65 岁的成年人以及 19-64 岁患有肺炎球菌疾病某些风险的成年人使用 PCV，如果他们没有接种 PCV 或疫苗接种史未知。以前，选项包括 20 价 PCV（PCV20;普雷夫纳20;惠氏制药公司）单独或 15 价 PCV（PCV15;VAXNEUVANCE;Merck Sharp & Dohme， LLC）与23价肺炎球菌多糖疫苗（PPSV23;肺炎 23;Merck Sharp & Dohme， LLC）。对于以 13 价 PCV 开始肺炎球菌疫苗接种系列的成年人，存在使用 PCV20 的其他建议（PCV13;普雷夫纳13;Wyeth Pharmaceuticals， Inc.）。ACIP 肺炎球菌疫苗工作组采用 Evidence to Recommendations 框架来指导其对美国成年人 PCV21 疫苗接种的审议。2024 年 6 月 27 日，ACIP 建议目前推荐 PCV 的 ≥19 岁成年人可以选择单剂 PCV21。PCV 的适应证与以前的建议没有变化。本报告总结了这些建议所考虑的证据，并为使用 PCV21 提供了临床指导。